ABSTRACT
Objective: We analyzed the effect of implementing a flash glucose monitoring (FGM) technology in a public health care system with universal coverage on the rate of severe hypoglycemia requiring urgent care in adults with type 1 diabetes mellitus (T1DM). Methods: Using a comprehensive regional dataset, we extracted emergency care codes with hypoglycemia in individuals with T1DM who initiated the use of FGM in Andalucia, Spain, from January 1, 2020, to December 31, 2021. Severe hypoglycemia was defined as a confirmed blood glucose <70 mg/dL, which required the urgent dispatch of an emergency medical service (EMS) for onsite management. We compared hypoglycemic events reported in the 12 months before and after the initiation of FGM to determine the population incidence rates. Results: A total of 13,616 participants with a mean age of 43.7 ± 13.5 years were included. The follow-up periods were 23.4 and 24.8 months before and after FGM. There were 969 and 737 cases of hypoglycemia before and after the initiation of FGM. The baseline incidence rate was 358.58 episodes per 10,000 person-years, which decreased to 260.9 at the end of the follow-up (rate-ratio 0.72 [0.66; 0.80]). The reduction in hypoglycemia was significant in individuals aged ≥60 years (rate-ratio 0.40 [0.28; 0.55]) and males (0.64 [0.56; 0.72]). In addition, there was a reduction in the overall median HbA1c of -0.35% (95% CI [-0.38; -0.33], P < 0.001). Conclusion: The implementation of FGM systems in a public health care system as a provision for adults with T1DM was associated with significant reductions in the rate of severe hypoglycemic events that required urgent EMS care.
ABSTRACT
Background: Glucagon-like peptide-1 receptor-agonists (GLP-1ra), such as semaglutide, have emerged as promising treatments, demonstrating sustained weight reduction and metabolic benefits. This study aims to assess the impact of oral and subcutaneous semaglutide on body composition and metabolic parameters in patients with T2DM and obesity. Methods: A 24-week quasi-experimental retrospective study including adults with T2DM and obesity (BMI ≥ 30 kg/m²) who were treated with either daily-oral or weekly-subcutaneous semaglutide. Body composition was measured using bioelectrical impedance analysis, evaluating fat mass, fat-free mass, total body water, skeletal muscle mass, and whole-body phase angle. Analytical parameters included lipid profile and glycaemic control. Statistical analyses were performed using SPSS v.26. Results: Participants (n=88) experienced significant weight loss after treatment with semaglutide (9.5% in subcutaneous, 9.4% in oral, P<0.001). Weight reduction primarily resulted from fat mass reduction without substantial lean mass compromise. Visceral fat area decreased, whiles phase-angle remained stable. Improvements in lipid profiles and glycaemic control were observed, with a decrease in both HbA1c and insulin requirements. Multivariate analysis demonstrated comparable impacts of oral and subcutaneous semaglutide on body composition. Conclusion: Semaglutide, administered orally or subcutaneously, demonstrated positive effects on body composition, metabolic and glycaemic control in patients with T2DM and obesity. This real-world study highlights the potential of bioelectrical impedance analysis in assessing antidiabetic drugs' impact on body composition, providing valuable insights for future research and clinical applications.
Subject(s)
Body Composition , Diabetes Mellitus, Type 2 , Glucagon-Like Peptides , Hypoglycemic Agents , Obesity , Humans , Glucagon-Like Peptides/therapeutic use , Glucagon-Like Peptides/administration & dosage , Diabetes Mellitus, Type 2/drug therapy , Body Composition/drug effects , Male , Female , Middle Aged , Retrospective Studies , Obesity/drug therapy , Adult , Hypoglycemic Agents/therapeutic use , Aged , Weight Loss/drug effects , Blood Glucose/drug effects , Blood Glucose/metabolismABSTRACT
BACKGROUND AND AIMS: The use of diabetes technologies is increasing worldwide, with health systems facilitating improved access to devices. Continuous glucose monitoring is a complex intervention that provides information on glucose concentration, rate and direction of change, historical data and alerts and alarms for extremes of glucose. These data do not themselves change glycaemia and require translation to a meaningful action for impact. It is, therefore, crucial that such systems advance to better meet the needs of individuals using them. METHODS: Narrative review of the use of, engagement with, limitations and unmet needs of continuous glucose monitoring systems. RESULTS: CGM devices have made a significant contribution to the self-management of diabetes; however, challenges with access and user experience persist, with multiple limitations to uptake and benefit. These limitations include physical size and implementation, with associated stigma, alarm fatigue, sleep disturbance and the challenge of addressing large volumes of real-time data. Greater personalisation throughout the continuous glucose monitoring journey, with a focus on usability, may improve the benefits derived from the device and reduce the burden of self-management. Healthcare professionals may have unconscious biases that affect the provision of continuous glucose monitors due to deprivation, education, age, ethnicity and other characteristics. CONCLUSIONS: Continuous glucose monitoring exerts a dose-dependent response; the more it is used, the more effective it is. For optimal use, continuous glucose monitors must not just reduce the burden of management in one dimension but facilitate net improvement in all domains of self-management for all users.
Subject(s)
Blood Glucose Self-Monitoring , Humans , Blood Glucose Self-Monitoring/instrumentation , Blood Glucose Self-Monitoring/methods , Blood Glucose/metabolism , Blood Glucose/analysis , Diabetes Mellitus/blood , Diabetes Mellitus/therapy , Diabetes Mellitus, Type 1/blood , Diabetes Mellitus, Type 1/drug therapy , Self-Management/methodsABSTRACT
Objective: To assess the clinical impact of flash glucose monitoring (FGM) systems on fear of hypoglycemia (FoH) and quality of life in adults with type 1 diabetes mellitus (T1DM). Methods: Prospective quasi-experimental study with a 12-month follow-up. People with T1DM (18-80 years old) and self-monitoring by blood capillary glycemia controls were included. The FH15 questionnaire, a survey validated in Spanish in a comparable study population, was used to diagnose FoH with a cutoff point of 28 points. Results: A total of 181 participants were included, with a FoH prevalence of 69% (n = 123). A mean reduction in FH15 score of -4 points (95% confidence interval [-5.5 to -3]; P < 0.001) was observed, along with an improvement in quality of life (EsDQOL-test (Diabetes Quality of Life, Spanish version), -7 points [-10; -4], P < 0.001) and satisfaction with treatment (Diabetes Treatment Satisfaction questionnaire, self-reported version [DTSQ-s] test, +4.5 points [4; 5.5], P < 0.001). At the end of the follow-up, 64.2% of the participants saw an improved FoH intensity, compared to 35.8% who scored the same or higher. This improvement in FoH status was associated with a higher time-in-range at the end of the follow-up (P = 0.003), as well as a lower time spent in hyperglycemia (P = 0.005). In addition, it was linked to participants with a high baseline FoH levels (P < 0.001) and those who were university degree holders (P = 0.07). Conclusions: FGM is associated with an overall reduction of FoH in adults with T1DM and with an increase in their quality of life. Nevertheless, a significant percentage of patients may experience an increase of this phenomenon leading to clinical repercussions and a profound impact on quality of life.
Subject(s)
Blood Glucose Self-Monitoring , Diabetes Mellitus, Type 1 , Fear , Hypoglycemia , Quality of Life , Humans , Diabetes Mellitus, Type 1/psychology , Diabetes Mellitus, Type 1/blood , Diabetes Mellitus, Type 1/drug therapy , Adult , Blood Glucose Self-Monitoring/psychology , Male , Female , Fear/psychology , Middle Aged , Hypoglycemia/psychology , Hypoglycemia/blood , Hypoglycemia/chemically induced , Aged , Prospective Studies , Young Adult , Adolescent , Blood Glucose/analysis , Aged, 80 and over , Surveys and QuestionnairesABSTRACT
No disponible
Subject(s)
Humans , Blood Glucose Self-Monitoring/methods , Hyperglycemia/prevention & control , Hypoglycemic Agents/administration & dosage , Diabetes Mellitus/drug therapy , Blood Glucose/analysis , Hypoglycemia/prevention & control , Drug Monitoring/methods , Diabetes Complications/prevention & controlABSTRACT
В 2004 году в рамках комплексного плана лечения диабета в Андалузии была разработана программа раннего выявления диабетической ретинопатии. В регионе проживает 8,4 млн. человек; по оценкам, уровень заболеваемости сахарным диабетом составляет около 12%. В настоящее время в рамках программы было обследовано 424 648 пациентов, выполнено 753 523 ретинографий, и охват целевого населения достиг 95%. Программа способствует более широкому вовлечению специалистов первичной медико-санитарной помощи и использованию цифровых решений.
Subject(s)
Diabetes Mellitus , Diabetic Retinopathy , Early Diagnosis , Primary Health Care , SpainABSTRACT
In 2004, a programme for early detection of diabetic retinopathy was introduced within the comprehensive plan for diabetes in Andalusia. The region has 8.4 million inhabitants and an estimated rate of diabetes mellitus of about 12%. Currently, 424 648 patients have participated in the programme, with 753 523 retinographies performed, reaching 95% of the target population. The programme enhances the participation of primary health care professionals and the use of digital solutions.
Subject(s)
Diabetes Mellitus , Diabetic Retinopathy , Early Diagnosis , Primary Health Care , SpainABSTRACT
No disponible
Subject(s)
Humans , Diabetes Mellitus, Type 1/drug therapy , Insulin Infusion Systems , Infusions, Subcutaneous/methods , Risk Factors , Cardiovascular Diseases/epidemiologyABSTRACT
No disponible
Subject(s)
Aged , Humans , Male , Pancreatitis/diagnosis , Autoimmune Diseases/diagnosis , Diabetes Mellitus, Type 2/diagnosis , Diabetes Mellitus, Type 2/drug therapy , Pancreatitis/pathology , Pancreatitis/drug therapy , Pancreatitis/complications , Cholangiopancreatography, Endoscopic Retrograde , Endosonography , Carcinoma, Pancreatic Ductal/diagnosis , Diagnosis, Differential , Blood Glucose/metabolism , Adrenal Cortex Hormones/therapeutic useABSTRACT
INTRODUCCIÓN: En 2009, la Sociedad Andaluza de Endocrinología y Nutrición diseñó un protocolo de insulinización subcutánea para pacientes hospitalizados no críticos («Protocolo de insulinización hospitalaria para el paciente no crítico» [PIH]), adoptado dentro del Sistema Sanitario Público Andaluz. OBJETIVOS: Analizar la implementación del PIH en hospitales de tercer nivel del Sistema Sanitario Público Andaluz. MÉTODO: Estudio multicéntrico descriptivo transversal en 8 hospitales andaluces de tercer nivel, mediante muestreo aleatorizado de pacientes ingresados ≥ 48 h, con DM (n = 306), en 5 servicios médicos (SM) y 2 quirúrgicos (SQ). La DM tipo 1, DM por trastornos específicos, soporte nutricional artificial, tratamiento esteroideo y gestación fueron criterios de exclusión. RESULTADOS: Se incluyeron 288 pacientes (varones 62,5%; 70,3 ± 10,3 años; 71,5% SM y 28,5% SQ). El régimen insulínico basal-bolus-corrección se instauró en el 55,9% (IC 95%: 50,5 - 61,2%); 63,1% SM vs. 37,8% SQ (p < 0,05). Las alternativas al régimen insulínico basal-bolus-corrección fueron: pautas móviles de insulina rápida (43,7%), dieta (31,3%), antidiabéticos orales (17,2%), premezclas (1,6%) y otras (6,2%). En pacientes tratados previamente con antidiabéticos orales, la dosis de insulina durante el ingreso fue 0,32 ± 0,1 UI/kg/día. En pacientes tratados previamente con insulina, la dosis de insulina durante el ingreso se incrementó en un 17% [-13-53] y en pacientes con terapia combinada, en 26,4% [-6-100]. Las pautas correctoras empleadas para < 40UI/día y 40-80UI/día fueron las recomendadas en el 72,2% y el 56,7%, respectivamente. Se solicitó HbA1c en el 23,6% (IC 95%: 18,8-28,8); 27,7% SM vs. 13,3% SQ (p < 0,05). CONCLUSIONES: Son recomendables estrategias para aumentar la implantación del PIH, especialmente en servicios quirúrgicos. Las pautas móviles de insulina rápida son la alternativa más frecuente al régimen insulínico basal-bolus-corrección. Es preciso fomentar la valoración del control metabólico al ingreso
INTRODUCTION: In 2009, the Andalusian Society of Endocrinology and Nutrition designed a protocol for subcutaneous insulin treatment in hospitalized non-critically ill patients (HIP). OBJECTIVE: To analyze implementation of HIP at tertiary care hospitals from the Andalusian Public Health System. Method A descriptive, multicenter study conducted in 8 tertiary care hospitals on a random sample of non-critically ill patients with diabetes/hyperglycemia (n = 306) hospitalized for ≥ 48 hours in 5 non-surgical (SM) and 2 surgical (SQ) departments. Type 1 and other specific types of diabetes, pregnancy and nutritional support were exclusion criteria. RESULTS: 288 patients were included for analysis (62.5% males; 70.3 ± 10.3 years; 71.5% SM, 28.5% SQ). A scheduled subcutaneous insulin regimen based on basal-bolus-correction protocol was started in 55.9% (95% CI: 50.5-61.2%) of patients, 63.1% SM vs. 37.8% SQ (P < .05). Alternatives to insulin regimen based on basal-bolus-correction included sliding scale insulin (43.7%), diet (31.3%), oral antidiabetic drugs (17.2%), premixed insulin (1.6%), and others (6.2%). For patients previously on oral antidiabetic drugs, in-hospital insulin dose was 0.32 ± 0.1 IU/kg/day. In patients previously on insulin, in-hospital insulin dose was increased by 17% [-13-53], and in those on insulin plus oral antidiabetic drugs, in-hospital insulin dose was increased by 26.4% [-6-100]. Supplemental insulin doses used for < 40IU/day and 40-80 IU/day were 72.2% and 56.7% respectively. HbA1c was measured in 23.6% of patients (95CI%: 18.8-28.8); 27.7% SM vs. 13.3% SQ (P < .05). CONCLUSIONS: Strategies are needed to improve implementation of the inpatient subcutaneous insulin protocol, particularly in surgical departments. Sliding scale insulin is still the most common alternative to insulin regimen based on basal-bolus-correction scheduled insulin. Metabolic control assessment during hospitalization should be encouraged
Subject(s)
Humans , Insulin Infusion Systems , Diabetes Mellitus/drug therapy , Insulin/administration & dosage , Hospitalization , Infusions, Subcutaneous , /methods , Clinical ProtocolsABSTRACT
Las cifras del estudio Di@bet.es en España son contundentes: la diabetes afecta al 13,8% de la población española. Pero si los datos estadísticos son alarmantes, el mayor problema lo constituye el ritmo de crecimiento, y las previsiones calculan en poco tiempo proporciones pandémicas de diabetes tipo 2 que pondrán en riesgo el estado de bienestar. Por ello, la diabetes no solo representa un desafío importante para los servicios de salud, sino que pasa a ser un reto para los Ministerios de Sanidad y Economía. La tecnología se ha convertido en una herramienta imprescindible en la atención de calidad del paciente con diabetes, pues facilita los procesos de atención y cuidados para obtener un buen control metabólico y prevenir las complicaciones. Las bombas de insulina, los sensores de glucosa y la automonitorización de la glucemia capilar ya han probado su eficiencia, y la telemedicina está en vías de hacerlo. Los costes indirectos de la diabetes en España son mucho más elevados que los directos, lo cual no deja de ser una paradoja que debemos invertir. La optimización de los recursos dependerá de la habilidad que tengamos los profesionales y la administración para implantar y mantener la innovación tecnológica en todos sus niveles y hacerla eficaz en la ecuación que examina los datos económicos y los beneficios. Los análisis de coste-efectividad y coste-utilidad son necesarios para establecer prioridades y permitir tomar decisiones de gestión sanitaria, que en el caso de enfermedades tan prevalentes como la diabetes tienen repercusiones directas en el gasto sanitario
Di@bet.es study results are impressive, showing that diabetes affects 13.8% of the Spanish population. Not only the statistical facts are alarming, but the increasing incidence of this disease is a major problem, as pandemic proportions of type 2 diabetes are expected. Thus, the study of diabetes represents a challenge not only for health services, but also for the Ministries of Health and Finance. Technology has become an essential tool in the quality care of patients with diabetes, as it helps in the healthcare processes to obtain an optimum metabolic balance and prevent possible complications. Insulin pumps, continuous glucose monitoring and self-monitoring blood glucose have all proved their efficiency, and telemedicine it is making good progress. The indirect costs of diabetes in Spain are much higher than the direct ones, showing the importance of inverting the paradox. The optimization of resources depends not only on the ability of the physicians, but also the administration, to implant and sustain technological innovations in our system, and with that make it effective in terms of benefits. Cost-effectiveness and cost-utility analysis are needed to prioritize and allow health management services to make the correct choices for approaching this prevalent chronic disease
Subject(s)
Humans , Male , Female , Diabetes Mellitus/diagnosis , Diabetes Mellitus/pathology , Diabetes Mellitus/prevention & control , Diabetes Mellitus/therapy , Technology/instrumentation , Technology/methods , Technology/trends , Telemedicine/trends , Telemedicine , Efficiency/ethicsABSTRACT
No disponible
Subject(s)
Humans , Parathyroid Neoplasms/surgery , Parathyroidectomy/adverse effects , Fasciitis/etiology , Risk FactorsSubject(s)
Humans , Male , Adolescent , Ploidies , Klinefelter Syndrome/diagnosis , Aneuploidy , Hypogonadism/etiology , Sex Chromosome AberrationsABSTRACT
Objetivo: La recurrencia del hipertiroidismo de la enfermedad de Graves tras dar por finalizado un ciclo de antitiroideos, es frecuente. El objetivo de este trabajo es investigar de forma prospectiva la recaída del hipertiroidismo durante el mantenimiento de 5 años con dosis bajas de fármacos antitiroideos de síntesis. Material y método: Desde marzo de 1997 se reclutó para la intervención a todos los pacientes con hipertiroidismo de la enfermedad de Graves que acudían consecutivamente a una misma consulta, y habían alcanzado el eutiroidismo con dosis bajas de antitiroideos (2,5-5 mg/día de carbimazol o metimazol) en 2 revisiones sucesivas (10-12 meses). Se intentó mantener desde entonces, en lugar de suspenderlo, un tratamiento con estas dosis durante 5 años, y se estudió en ese intervalo la tasa de recaída del hipertiroidismo (grupo M, 53 pacientes). Desde la misma fecha (marzo de 1997), se recogieron también datos de los pacientes con hipertirodismo de la enfermedad de Graves que se revisaban consecutivamente en dicha consulta, pero a los que, con anterioridad a esa fecha, se les había suspendido la medicación antitiroidea al conseguir las mismas condiciones señaladas anteriormente; de igual modo se estudió la tasa de recurrencia del hipertiroidismo durante los 5 años que seguían a la suspensión (grupo R, histórico, control, 31 pacientes). Resultado principal: El hipertiroidismo recayó en 12/53 (22,64%) pacientes del grupo M, por 24/31 (77,42%) pacientes del grupo R (p < 0,000). Conclusiones: La tasa de recaída del hipertiroidismo de la enfermedad de Graves mientras se mantenían dosis bajas de fármacos antitiroideos de síntesis fue menor, de forma significativa, que la recogida tras suspenderlos (AU)
Objective: The relapse rate of Graves' hyperthyroidism after finishing an antithyroid cicle is high. The objective of this work was to prospectively investigate the relapse rate of Graves' hyperthyroidism (GH) in patients with maintenance of a low dose of antithyroid drug (ATD) therapy. Patients and method: From March 1997, all patients with GH consecutively attending the same center who remained euthyroid with low doses of synthetic ATD (carbimazole or methimazole: 2.5-5 mg/day) on 2 consecutive follow-up visits (at 10-12 months) were included in this study. Instead of withdrawing ATD, the aim was to continue with this low dose for a 5-year period (group M: 53 patients). From March 1997, data were also collected from patients with GH who were consecutively followed-up and who, meeting the criteria for inclusion in group M, had stopped receiving ATD before the start of the study (March 1997) (group R: 31 patients). Main outcome: GH relapse was observed in 12/53 patients in group M (22.64%) and in 24/31 patients in group R (77.42%) (p < 0.000). Conclusions: The GH relapse rate was significantly lower with long-term maintenance of a low dose of ATD than with therapy withdrawal (AU)